STRATEC Biomedical (SBS) Financial Statements

6 Followers

STRATEC Biomedical Financial Overview

STRATEC Biomedical's market cap is currently €215.16M. The company's EPS TTM is €-0.02; its P/E ratio is -15.70; and it has a dividend yield of 2.71%. STRATEC Biomedical is scheduled to report earnings on April 28, 2026, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	€ 250.86M	€ 257.62M	€ 270.41M	€ 274.63M	€ 287.33M
Gross Profit	€ 64.22M	€ 76.39M	€ 68.16M	€ 79.49M	€ 87.71M
Operating Income	€ 8.59M	€ 28.18M	€ 28.12M	€ 42.00M	€ 49.63M
EBITDA	€ 27.19M	€ 47.34M	€ 43.16M	€ 57.53M	€ 66.52M
Net Income	€ -242.00K	€ 16.02M	€ 15.37M	€ 29.22M	€ 39.96M
Balance Sheet
Cash & Short-Term Investments	€ 23.06M	€ 48.73M	€ 34.22M	€ 24.07M	€ 48.72M
Total Assets	€ 443.38M	€ 445.06M	€ 466.58M	€ 397.50M	€ 368.52M
Total Debt	€ 132.13M	€ 130.53M	€ 141.37M	€ 87.15M	€ 85.30M
Net Debt	€ 109.08M	€ 83.37M	€ 107.84M	€ 64.48M	€ 38.11M
Total Liabilities	€ 206.06M	€ 202.53M	€ 233.25M	€ 172.32M	€ 162.77M
Stockholders' Equity	€ 237.32M	€ 242.53M	€ 233.33M	€ 225.18M	€ 205.76M
Cash Flow
Free Cash Flow	€ -9.71M	€ 30.52M	€ 2.00M	€ -8.74M	€ 43.24M
Operating Cash Flow	€ -433.00K	€ 48.71M	€ 19.43M	€ 10.28M	€ 63.47M
Investing Cash Flow	€ -16.80M	€ -15.97M	€ -44.16M	€ -19.00M	€ -20.13M
Financing Cash Flow	€ -6.30M	€ -20.30M	€ 35.44M	€ -14.11M	€ -34.33M

Currency in EUR

STRATEC Biomedical Earnings and Revenue History

Income Statement >

STRATEC Biomedical Debt to Assets

Balance Sheet >

STRATEC Biomedical Cash Flow

Cash Flow >

STRATEC Biomedical Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >